-
EP4054623
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4054623
| EP4054623 - COMBINATION OF A T CELL THERAPY AND (S)-3-[4-(4-MORPHOLIN-4 YLMETHYL-BENZYLOXY)-L-OXO-L,3-DIHYDRO-ISOINDOL-2-YL]- PIPERIDINE-2,6-DIONE [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 12.08.2022 Database last updated on 19.10.2024 | |
| Former | The international publication has been made Status updated on 14.05.2021 | ||
| Former | unknown Status updated on 14.12.2020 | Most recent event Tooltip | 05.10.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Juno Therapeutics, Inc. 400 Dexter Ave. N, Suite 1200 Seattle, WA 98109 / US | [2022/37] | Inventor(s) | 01 /
PORTS, Michael 400 Dexter Ave. N Suite 1200 Seattle, WA 98109 / US | 02 /
HASSKARL, Jens Route de Perreux 1 2017 Boudry / CH | 03 /
MONTHEARD, Sandrine Route de Perreux 1 2017 Boudry / CH | 04 /
POURDEHNAD, Michael 86 Morris Avenue Summit, NJ 07901 / US | 05 /
PULHAM, Tim Route de Perreux 1 2017 Boudry / CH | 06 /
QIN, Jim 400 Dexter Ave. N Suite 1200 Seattle, WA 98109 / US | [2022/37] | Representative(s) | Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB | [N/P] |
| Former [2022/37] | Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | Application number, filing date | 20819955.4 | 06.11.2020 | [2022/37] | WO2020US59550 | Priority number, date | US201962932500P | 07.11.2019 Original published format: US 201962932500 P | US202063016977P | 28.04.2020 Original published format: US 202063016977 P | [2022/37] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021092498 | Date: | 14.05.2021 | Language: | EN | [2021/19] | Type: | A1 Application with search report | No.: | EP4054623 | Date: | 14.09.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 14.05.2021 takes the place of the publication of the European patent application. | [2022/37] | Search report(s) | International search report - published on: | EP | 14.05.2021 | Classification | IPC: | A61K39/00, C07K14/725, A61P35/00, A61K31/5377 | [2022/37] | CPC: |
C07K14/7051 (EP,IL,KR);
A61K31/5377 (EP,IL,KR,US);
A61K39/4611 (EP,IL,KR);
A61K35/17 (KR,US);
A61K31/664 (KR,US);
A61K31/7076 (KR,US);
A61K39/001112 (KR);
A61K39/4631 (EP,IL,KR);
A61K39/464412 (EP,IL,KR);
A61P35/00 (US);
A61P35/02 (EP,IL,KR);
A61K2039/5156 (KR);
A61K2039/545 (KR);
A61K2039/804 (EP,IL,KR);
A61K2239/48 (EP,IL,KR);
A61K2300/00 (IL,KR)
(-)
| C-Set: |
A61K31/5377, A61K2300/00 (EP);
A61K39/464412, A61K2300/00 (IL,EP) | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/37] | Extension states | BA | 31.05.2022 | ME | 31.05.2022 | Validation states | KH | 31.05.2022 | MA | 31.05.2022 | MD | 31.05.2022 | TN | 31.05.2022 | Title | German: | KOMBINATION AUS EINER T-ZELLTHERAPIE UND (S)-3-[4-(4-MORPHOLIN-4 YLMETHYL-BENZYLOXY)-L-OXO-L,3-DIHYDRO-ISOINDOL-2-YL]-PIPERIDIN-2,6-DION | [2022/37] | English: | COMBINATION OF A T CELL THERAPY AND (S)-3-[4-(4-MORPHOLIN-4 YLMETHYL-BENZYLOXY)-L-OXO-L,3-DIHYDRO-ISOINDOL-2-YL]- PIPERIDINE-2,6-DIONE | [2022/37] | French: | COMBINAISON D'UNE THÉRAPIE PAR LYMPHOCYTES T ET (S)-3-[4-(4-MORPHOLIN-4 YLMÉTHYL-BENZYLOXY)-L-OXO-L, 3-DIHYDRO-ISOINDOL-2-YL]-PIPÉRIDINE -2,6-DIONE | [2022/37] | Entry into regional phase | 31.05.2022 | National basic fee paid | 31.05.2022 | Designation fee(s) paid | 31.05.2022 | Examination fee paid | Examination procedure | 31.05.2022 | Examination requested [2022/37] | 31.05.2022 | Date on which the examining division has become responsible | 22.12.2022 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 13.10.2022 | Renewal fee patent year 03 | 29.09.2023 | Renewal fee patent year 04 | 04.10.2024 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [YD]US2014045843 (SCHAFER PETER H [US], et al); | [Y]US2014046057 (COHEN BENJAMIN M [US], et al); | [Y]WO2018204427 (JUNO THERAPEUTICS INC [US]); | [Y]WO2018223101 (JUNO THERAPEUTICS INC [US]); | [XP]WO2020097403 (JUNO THERAPEUTICS INC [US]); | by applicant | US4452773 | US4690915 | US4795698 | US5200084 | US5219740 | EP0452342 | WO0014257 | US6040177 | US6060273 | US6207453 | US6410319 | US6451995 | US2002131960 | US2003170238 | US7070995 | US2007116690 | US7265209 | US7354762 | US7446190 | US7446179 | US7446191 | WO2009072003 | WO2010033140 | US2011003380 | WO2011100380 | WO2012129514 | US8324353 | US8339645 | EP2537416 | US8389282 | US8398282 | WO2013071154 | US2013149337 | US8479118 | WO2013123061 | WO2013126726 | US2013287748 | WO2013166321 | US2014045843 | WO2014031687 | WO2014055668 | US8802374 | WO2014190273 | US8911993 | WO2015095895 | US9221788 | US2016152723 | WO2018023100 | US10080801 | WO1991US08442 | WO1994US05601 |